Amlodipine/atorvastatin single pill for the management of hypertensive patients with additional cardiovascular risk factors (Q40347884)

19 September 2017

title

Amlodipine/atorvastatin single pill for the management of hypertensive patients with additional cardiovascular risk factors (English)

1 reference

19 September 2017

Roy Blank

1 reference

19 September 2017

publication date

1 March 2006

1 reference

19 September 2017

1 reference

19 September 2017

1 reference

19 September 2017

1 reference

19 September 2017

page(s)

145-159

1 reference

Selected major risk factors and global and regional burden of disease

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Lipids, risk factors and ischaemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Fifty years of Framingham Study contributions to understanding hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

High blood pressure and associated cardiovascular risk factors in France

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Expanding the definition and classification of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Incremental effectiveness of amlodipine besylate in the treatment of hypertension with single and multiple medication regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Metabolism and kinetics of amlodipine in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

The effect of amlodipine on ambulatory blood pressure in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

Evidence that new antihypertensives are superior to older drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.2.2.145

21 January 2018

Identifiers

DOI

10.2217/14796678.2.2.145

1 reference

19 September 2017

1 reference